Patent · US Active

Anti-PD-L1 antibodies and diagnostic uses thereof

US11530269B2 · kind B2 · utility

0Cited by
10References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 11, 2020
Grant dateDec 20, 2022
Priority date—
Expiry dateFeb 9, 2041

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.